Use of interleukin 17E for the treatment of cancer
US8287851B2 · kind B2 · utility
4Cited by
4References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 8, 2006 |
| Grant date | Oct 16, 2012 |
| Priority date | — |
| Expiry date | Nov 26, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of interleukin 17E to inhibit tumor growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumor growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.